Leukotriene Signaling as a Target in α-Synucleinopathies
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are two common types of α-synucleinopathies and represent a high unmet medical need. Despite diverging clinical manifestations, both neurodegenerative diseases share several facets of their complex pathophysiology. Apart from α-synuclein a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/12/3/346 |
| _version_ | 1797472663235461120 |
|---|---|
| author | Katharina Strempfl Michael S. Unger Stefanie Flunkert Andrea Trost Herbert A. Reitsamer Birgit Hutter-Paier Ludwig Aigner |
| author_facet | Katharina Strempfl Michael S. Unger Stefanie Flunkert Andrea Trost Herbert A. Reitsamer Birgit Hutter-Paier Ludwig Aigner |
| author_sort | Katharina Strempfl |
| collection | DOAJ |
| description | Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are two common types of α-synucleinopathies and represent a high unmet medical need. Despite diverging clinical manifestations, both neurodegenerative diseases share several facets of their complex pathophysiology. Apart from α-synuclein aggregation, an impairment of mitochondrial functions, defective protein clearance systems and excessive inflammatory responses are consistently observed in the brains of PD as well as DLB patients. Leukotrienes are lipid mediators of inflammatory signaling traditionally known for their role in asthma. However, recent research advances highlight a possible contribution of leukotrienes, along with their rate-limiting synthesis enzyme 5-lipoxygenase, in the pathogenesis of central nervous system disorders. This review provides an overview of in vitro as well as in vivo studies, in summary suggesting that dysregulated leukotriene signaling is involved in the pathological processes underlying PD and DLB. In addition, we discuss how the leukotriene signaling pathway could serve as a future drug target for the therapy of PD and DLB. |
| first_indexed | 2024-03-09T20:04:31Z |
| format | Article |
| id | doaj.art-1cd98421cb934ffd97049176fa95cf40 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-09T20:04:31Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-1cd98421cb934ffd97049176fa95cf402023-11-24T00:34:35ZengMDPI AGBiomolecules2218-273X2022-02-0112334610.3390/biom12030346Leukotriene Signaling as a Target in α-SynucleinopathiesKatharina Strempfl0Michael S. Unger1Stefanie Flunkert2Andrea Trost3Herbert A. Reitsamer4Birgit Hutter-Paier5Ludwig Aigner6Institute of Molecular Regenerative Medicine, Paracelsus Medical University, 5020 Salzburg, AustriaInstitute of Molecular Regenerative Medicine, Paracelsus Medical University, 5020 Salzburg, AustriaQPS Austria GmbH, Neuropharmacology, 8074 Grambach, AustriaUniversity Clinic of Ophthalmology and Optometry, Research Program for Ophthalmology and Glaucoma Research, Paracelsus Medical University, 5020 Salzburg, AustriaUniversity Clinic of Ophthalmology and Optometry, Research Program for Ophthalmology and Glaucoma Research, Paracelsus Medical University, 5020 Salzburg, AustriaQPS Austria GmbH, Neuropharmacology, 8074 Grambach, AustriaInstitute of Molecular Regenerative Medicine, Paracelsus Medical University, 5020 Salzburg, AustriaParkinson’s disease (PD) and dementia with Lewy bodies (DLB) are two common types of α-synucleinopathies and represent a high unmet medical need. Despite diverging clinical manifestations, both neurodegenerative diseases share several facets of their complex pathophysiology. Apart from α-synuclein aggregation, an impairment of mitochondrial functions, defective protein clearance systems and excessive inflammatory responses are consistently observed in the brains of PD as well as DLB patients. Leukotrienes are lipid mediators of inflammatory signaling traditionally known for their role in asthma. However, recent research advances highlight a possible contribution of leukotrienes, along with their rate-limiting synthesis enzyme 5-lipoxygenase, in the pathogenesis of central nervous system disorders. This review provides an overview of in vitro as well as in vivo studies, in summary suggesting that dysregulated leukotriene signaling is involved in the pathological processes underlying PD and DLB. In addition, we discuss how the leukotriene signaling pathway could serve as a future drug target for the therapy of PD and DLB.https://www.mdpi.com/2218-273X/12/3/346leukotriene signaling pathwayParkinson’s diseasedementia with Lewy bodiesα-synucleinopathyMontelukast |
| spellingShingle | Katharina Strempfl Michael S. Unger Stefanie Flunkert Andrea Trost Herbert A. Reitsamer Birgit Hutter-Paier Ludwig Aigner Leukotriene Signaling as a Target in α-Synucleinopathies Biomolecules leukotriene signaling pathway Parkinson’s disease dementia with Lewy bodies α-synucleinopathy Montelukast |
| title | Leukotriene Signaling as a Target in α-Synucleinopathies |
| title_full | Leukotriene Signaling as a Target in α-Synucleinopathies |
| title_fullStr | Leukotriene Signaling as a Target in α-Synucleinopathies |
| title_full_unstemmed | Leukotriene Signaling as a Target in α-Synucleinopathies |
| title_short | Leukotriene Signaling as a Target in α-Synucleinopathies |
| title_sort | leukotriene signaling as a target in α synucleinopathies |
| topic | leukotriene signaling pathway Parkinson’s disease dementia with Lewy bodies α-synucleinopathy Montelukast |
| url | https://www.mdpi.com/2218-273X/12/3/346 |
| work_keys_str_mv | AT katharinastrempfl leukotrienesignalingasatargetinasynucleinopathies AT michaelsunger leukotrienesignalingasatargetinasynucleinopathies AT stefanieflunkert leukotrienesignalingasatargetinasynucleinopathies AT andreatrost leukotrienesignalingasatargetinasynucleinopathies AT herbertareitsamer leukotrienesignalingasatargetinasynucleinopathies AT birgithutterpaier leukotrienesignalingasatargetinasynucleinopathies AT ludwigaigner leukotrienesignalingasatargetinasynucleinopathies |